Telix Pharmaceuticals has signed a memorandum of understanding with United Imaging to co-develop integrated theranostics workflows in the U.S.
The agreement pairs Telix's radiopharmaceutical pipeline and validated clinical protocols with United Imaging's scanner hardware, software, and AI capabilities, according to an announcement.
Initially, the companies will focus is TLX101-Px (Pixclara, F-18 floretyrosine), Telix's glioma PET imaging candidate, which is currently under U.S. Food and Drug Administration (FDA) new drug application review, with a target action date of September 11, 2026.
Early efforts will include scanning protocol optimization, workflow support tools development and validation, and launching pilot programs aligned with high-impact clinical applications, Telix noted.
